16-173598-T-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM4PP5_Very_Strong
The NM_000517.6(HBA2):āc.427T>Cā(p.Ter143GlnextTer31) variant causes a stop lost change. The variant allele was found at a frequency of 0.0000224 in 1,608,260 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Genomes: š 0.000040 ( 0 hom., cov: 25)
Exomes š: 0.000021 ( 1 hom. )
Consequence
HBA2
NM_000517.6 stop_lost
NM_000517.6 stop_lost
Scores
3
4
Clinical Significance
Conservation
PhyloP100: 4.12
Genes affected
HBA2 (HGNC:4824): (hemoglobin subunit alpha 2) The human alpha globin gene cluster located on chromosome 16 spans about 30 kb and includes seven loci: 5'- zeta - pseudozeta - mu - pseudoalpha-1 - alpha-2 - alpha-1 - theta - 3'. The alpha-2 (HBA2) and alpha-1 (HBA1) coding sequences are identical. These genes differ slightly over the 5' untranslated regions and the introns, but they differ significantly over the 3' untranslated regions. Two alpha chains plus two beta chains constitute HbA, which in normal adult life comprises about 97% of the total hemoglobin; alpha chains combine with delta chains to constitute HbA-2, which with HbF (fetal hemoglobin) makes up the remaining 3% of adult hemoglobin. Alpha thalassemias result from deletions of each of the alpha genes as well as deletions of both HBA2 and HBA1; some nondeletion alpha thalassemias have also been reported. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM4
Stoplost variant in NM_000517.6 Downstream stopcodon found after 154 codons.
PP5
Variant 16-173598-T-C is Pathogenic according to our data. Variant chr16-173598-T-C is described in ClinVar as [Pathogenic]. Clinvar id is 15624.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-173598-T-C is described in Lovd as [Pathogenic]. Variant chr16-173598-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HBA2 | NM_000517.6 | c.427T>C | p.Ter143GlnextTer31 | stop_lost | 3/3 | ENST00000251595.11 | NP_000508.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HBA2 | ENST00000251595.11 | c.427T>C | p.Ter143GlnextTer31 | stop_lost | 3/3 | 1 | NM_000517.6 | ENSP00000251595 | P1 | |
HBA2 | ENST00000482565.1 | n.563T>C | non_coding_transcript_exon_variant | 2/2 | 1 | |||||
ENST00000702607.1 | n.63A>G | non_coding_transcript_exon_variant | 1/1 | |||||||
HBA2 | ENST00000397806.1 | c.331T>C | p.Ter111GlnextTer31 | stop_lost | 3/3 | 2 | ENSP00000380908 |
Frequencies
GnomAD3 genomes AF: 0.0000403 AC: 6AN: 149046Hom.: 0 Cov.: 25
GnomAD3 genomes
AF:
AC:
6
AN:
149046
Hom.:
Cov.:
25
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000563 AC: 14AN: 248854Hom.: 0 AF XY: 0.0000445 AC XY: 6AN XY: 134854
GnomAD3 exomes
AF:
AC:
14
AN:
248854
Hom.:
AF XY:
AC XY:
6
AN XY:
134854
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000206 AC: 30AN: 1459094Hom.: 1 Cov.: 33 AF XY: 0.0000165 AC XY: 12AN XY: 725622
GnomAD4 exome
AF:
AC:
30
AN:
1459094
Hom.:
Cov.:
33
AF XY:
AC XY:
12
AN XY:
725622
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000402 AC: 6AN: 149166Hom.: 0 Cov.: 25 AF XY: 0.0000274 AC XY: 2AN XY: 72884
GnomAD4 genome
AF:
AC:
6
AN:
149166
Hom.:
Cov.:
25
AF XY:
AC XY:
2
AN XY:
72884
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
6
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10Other:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
alpha Thalassemia Pathogenic:5Other:2
Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Jul 27, 2022 | PS4, PM1, PM4, PP1, PP5 - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 02, 2021 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | Variant interpretted as Pathogenic and reported on 07-24-2019 by Lab or GTR ID 500068. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Dec 03, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 20, 2019 | NM_000517.4(HBA2):c.427T>C(*143Qext*31, aka Hb Constant Spring) is classified as pathogenic in the context of alpha thalassemia and is classified as an alpha-plus variant. Sources cited for classification include the following: PMID 4944483, 12393486, 7327587, 2298455 and 17164653. Classification of NM_000517.4(HBA2):c.427T>C(*143Qext*31, aka Hb Constant Spring) is based on the following criteria: This variant is predicted to result in protein elongation in a gene and is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Nov 05, 2020 | 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0108 - This gene is known to be associated with both recessive and dominant disease (OMIM). (N) 0208 - Variant is predicted to result in an elongated protein (exon 3 of 3). (P) 0251 - Variant is heterozygous. (N) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (16 heterozygotes, 0 homozygotes). (P) 0702 - Comparable variants have strong previous evidence for pathogenicity (ClinVar). Four other elongated protein have been reported as pathogenic. (P) 0801 - Strong previous evidence of pathogenicity in multiple unrelated individuals. This is the most common pathogenic mutation reported in alpha thalassemia, known as the Hb Constant Sprint variant (ClinVar, PMID: 26757782). (P) 1206 - Variant is paternally inherited. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 25, 2022 | The variant eliminates the normal Stop codon and replaces it with a Glutamine codon, ultimately extending the protein by 31 amino acids at the C-terminal end of the protein; This variant is associated with the following publications: (PMID: 26757782, 24368026, 21077767, 24829075, 25523870, 23637094, 20931520, 3177365, 25897478, 26956449, 30626226, 30615015, 30275481, 34272389, 32925409, 32860378, 32338097, 29627922) - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 19, 2023 | The HBA2 c.427T>C (p.*143Glnext*31) variant disrupts the translation stop codon of the HBA2 mRNA and is predicted to cause abnormal HBA2 protein elongation. In the published literature and online databases, this variant has been reported to be damaging to HBA2 function and results in an unstable protein (PMID: 7969150 (1994)). Additionally, this variant has been reported in individuals with Hb H disease that are compound heterozygous with other pathogenic HBA2 variants, such as Hb Adana (PMIDs: 24829075 (2014), 27271331 (2016)), Hb Pakse (PMIDs: 7502632 (1995), 28244614 (2018), 30615015 (2019)), and Hb Quong (PMID: 26956449 (2016)). This variant is commonly seen with the SEA alpha-1 deletion (PMIDs: 11836160 (2002), 32925409 (2021), 36459106 (2023)). Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 30, 2023 | The Hb Constant Spring variant (HbCS, HBA2: c.427T>C; p.Ter143Gln, also known as Ter142Gln when numbered from the mature protein, rs41464951, HbVar ID: 703) is usually asymptomatic in the heterozygous state, but may be associated with microcytosis and mild hypochromia. Homozygosity for HbCS is characterized by overt hemolytic anemia, jaundice and splenomegaly, while HbCS paired with an alpha zero-thalassemia deletion commonly results in HbH disease (Lie-Injo 1974, Nguyen 2014, HbVar database). This variant is reported in ClinVar (Variation ID: 15624), and is found in the general population with an overall allele frequency of 0.006% (16/274,340 alleles) in the Genome Aggregation Database. This variant abolishes the canonical termination codon, resulting in an unstable, elongated protein (HbVar database). Based on available information, the HbCS variant is considered to be pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/hbvar.html Lie-Injo L et al. Homozygous state for Hb Constant Spring (slow-moving Hb X components). Blood. 1974 Feb;43(2):251-9. PMID: 4810076. Nguyen V et al. Hemoglobin Constant Spring is markedly high in women of an ethnic minority group in Vietnam: a community-based survey and hematologic features. Blood Cells Mol Dis. 2014 Apr;52(4):161-5. PMID: 24368026. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change disrupts the translational stop signal of the HBA2 mRNA. It is expected to extend the length of the HBA2 protein by 31 additional amino acid residues. This variant is present in population databases (rs41464951, gnomAD 0.07%). This protein extension has been observed in individual(s) with HBA2-related conditions (PMID: 2298455, 4944483, 12393486, 20507641). It is commonly reported in individuals of Southeast Asian ancestry (PMID: 2298455, 4944483, 12393486, 20507641). This variant is also known as Constant Spring. ClinVar contains an entry for this variant (Variation ID: 15624). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this protein extension affects HBA2 function (PMID: 6725554, 9057661). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. - |
Hemoglobin H disease, nondeletional Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1992 | - - |
Hemoglobin constant spring Other:1
other, no assertion criteria provided | literature only | OMIM | Sep 12, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
N;N
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at